MSI2 and neoplasm: Furthermore, 100% of the mice in the MDA-MB-231 (Scr-treated, MSI2-depleted) and Scr-treated clone #1 tumor-bearing groups exhibited tumor growth in the mammary fat pad; however, only 50% of the mice in the MSI2-depleted clone #1 tumor-bearing group exhibited discernable tumor growth (Table S2).